Perlegen and Bristol-Myers Squibb in Pharmacogenomics Deal

Dec 19, 2002

NEW YORK, Dec. 19-Perlegen Sciences will identify pharmacogenomic markers for Bristol-Myers Squibb, the company said today.

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.